Glenmark Pharmaceuticals has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) single dose vial. The company’s injection is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630].

According to IQVIA sales data for the 12-month period ending April 2026, the ProvayBlue Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of approximately USD 19 million.

Commenting on the launch, Marc Kikuchi, President and Business Head—North America, said, “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the US market.